about
Complement System Part II: Role in ImmunitySingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaIntegrative analysis to select cancer candidate biomarkers to targeted validation.The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput dataInsights into immune responses in oral cancer through proteomic analysis of saliva and salivary extracellular vesicles.A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva.Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal TransitionC1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1Complement-Mediated Regulation of Metabolism and Basic Cellular ProcessesToll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy.Role of the BrafV637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice.CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance.C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA.Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.The Complement Anaphylatoxins C5a and C3a Suppress IFN-β Production in Response to Listeria monocytogenes by Inhibition of the Cyclic Dinucleotide-Activated Cytosolic Surveillance Pathway.Innate immune mediators in cancer: between defense and resistance.The role of the complement system in cancer.Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes.Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity.Role of ADP receptors on platelets in the growth of ovarian cancer.Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma.Targeting complement-mediated immunoregulation for cancer immunotherapy.Complement in cancer: untangling an intricate relationship.[The complement system: a double edge sword in tumor progression].Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer.Complement as a Biological Tool to Control Tumor GrowthThe complement system in glioblastoma multiforme
P2860
Q28263460-C23873BF-3A20-4CB7-805C-18828DE3A5D0Q29615604-95880EB1-C0EB-4FCD-BDAA-CB4D458E026EQ30278389-E7777FC1-4FD1-43FB-AD08-FB4D69EE3ABEQ33592056-26AF08DD-73F4-44A9-ACFC-441507FBBA0CQ36250099-DCC11F9F-C915-46BF-AD48-70FFE4A38859Q36436952-4D027724-15AA-4D9D-A342-36CD44DE6DC6Q36495124-37690666-F193-4285-B2FE-22655860085CQ36541076-822E86AD-E6B7-4810-842B-3D4002E0338FQ36553594-FFC4D9BF-B9B5-40A6-895B-36B214605EA5Q37248499-989C4399-5089-4844-9624-4D14AA09C118Q37398348-C3644DC4-7016-4AF6-94B5-A35B68E35116Q37407271-1596FBD8-167C-4914-B587-EC1180761790Q37558112-347D10DA-49DA-43FC-B4F5-884985B39703Q37583589-EE7271ED-49C2-4959-B040-20814A35710CQ37709018-E34DBAA7-1C26-403E-8447-0D968AEF0972Q38621456-63006C78-18F8-4F35-8ED4-76C15D521387Q38895520-CE552077-B1A0-4E0B-A9A0-930CA9A5217EQ38919672-CA8C17EC-5409-494D-94FB-280EB01A7DA4Q38991015-83F66621-2542-4938-A34B-5F84CC2B08C8Q39156024-3E89E8A3-7212-4FFA-97CD-D1853BA4CF01Q39686133-117402D7-27CF-42B4-A7D7-FB66AC18AFC5Q40559319-AD279BE4-8325-4167-B98E-54A78AAFE33BQ41068034-800FECF9-C01B-4513-91B1-D8C71DE871E1Q41653522-D31DE0A2-B944-4D2B-9839-05FAC41F9F4BQ45869485-88E44E52-4D4A-4027-916B-6D0ED9B876CDQ47620768-B1D6C092-AE82-49AA-BBDA-AA0DD211E402Q47714757-4AE94AF3-60B3-40E0-81E1-BAC59D177E6EQ49461578-929305F4-A4A6-43D9-B598-65A5C5A32F7AQ49898514-7F4DE635-E2E7-4CA7-8935-A4D413E28E95Q50049007-523CD630-9CC9-455E-B984-25941A4563CFQ50243745-123EC85B-330D-448D-A8AA-59B0FDD4EB21Q50586476-6E68C33A-A3BE-43AE-847B-F80288B0799DQ55284109-8166E325-9E45-4F4A-8CAD-C2028A6D3B3FQ57492005-941D061C-5C2C-49EB-9D20-6B6F91704B1FQ58748412-57C3E890-3E58-4E3A-8C8C-55C1780BC831
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Autocrine effects of tumor-derived complement.
@ast
Autocrine effects of tumor-derived complement.
@en
type
label
Autocrine effects of tumor-derived complement.
@ast
Autocrine effects of tumor-derived complement.
@en
prefLabel
Autocrine effects of tumor-derived complement.
@ast
Autocrine effects of tumor-derived complement.
@en
P2093
P2860
P50
P1433
P1476
Autocrine effects of tumor-derived complement
@en
P2093
Anil K Sood
Behrouz Zand
Gabriel Lopez-Berestein
Heather J Dalton
Hee-Dong Han
Hernan G Vasquez
Justin Bottsford-Miller
Keith Baggerly
Min Soon Cho
P2860
P304
P356
10.1016/J.CELREP.2014.02.014
P577
2014-03-06T00:00:00Z